23andMe Layoffs
Industry Healthcare · Location SF Bay Area · United States · Subscribe (RSS)
23andMe has 3 publicly reported layoff rounds on record between June 9, 2023 and November 11, 2024. A total of about 346 employees were affected across these rounds.
Layoff history
23andMe cut more than 200 employees on November 11, 2024, a reduction of roughly 40% of its workforce, and simultaneously shut down its entire therapeutics division. The genetic testing company, which had seen its stock fall from a 2021 peak of over $300 per share to under $5, said the cuts would save more than $35 million annually. Clinical trials were to be wound down "as quickly as practical," and assets from the drug research programs, including cancer treatment studies, were put up for evaluation. CEO Anne Wojcicki called the actions "difficult but necessary" to put the company on "a more sustainable path" and refocus on its core consumer DNA testing and research partnerships. The restructuring carried approximately $12 million in severance and transition costs. The layoffs came weeks after the company's entire independent board had resigned in September, following Wojcicki's failed attempt to take the company private, and months after a cyberattack had exposed the genetic data of 6.9 million users.
Reason: Cost reduction and strategic refocus; therapeutics division discontinued
Source: wsj.com
23andMe disclosed a workforce reduction affecting its SF Bay Area operations in August 8, 2023. Approximately 71 roles were eliminated.
Source: streetinsider.com
23andMe disclosed a workforce reduction affecting its SF Bay Area operations in June 9, 2023. Approximately 75 roles were eliminated.
Source: genomeweb.com
Data for 23andMe is compiled from public WARN Act filings and reporting linked above. See our methodology.